MX2020002532A - Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. - Google Patents

Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.

Info

Publication number
MX2020002532A
MX2020002532A MX2020002532A MX2020002532A MX2020002532A MX 2020002532 A MX2020002532 A MX 2020002532A MX 2020002532 A MX2020002532 A MX 2020002532A MX 2020002532 A MX2020002532 A MX 2020002532A MX 2020002532 A MX2020002532 A MX 2020002532A
Authority
MX
Mexico
Prior art keywords
alcoholic
hepatic
invasive diagnosis
steatosis
hepatic fibrosis
Prior art date
Application number
MX2020002532A
Other languages
English (en)
Inventor
Rémy Hanf
John Brozek
Geneviève Cordonnier
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2020002532A publication Critical patent/MX2020002532A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un nuevo método no invasivo para el diagnóstico de una esteatosis hepática no alcohólica, en particular, esteatohepatitis no alcohólica y/o fibrosis hepática.
MX2020002532A 2017-09-18 2018-09-14 Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. MX2020002532A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306201 2017-09-18
PCT/EP2018/074975 WO2019053233A1 (en) 2017-09-18 2018-09-14 NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS

Publications (1)

Publication Number Publication Date
MX2020002532A true MX2020002532A (es) 2020-07-20

Family

ID=60001810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002532A MX2020002532A (es) 2017-09-18 2018-09-14 Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.

Country Status (15)

Country Link
US (1) US11519034B2 (es)
EP (1) EP3684954B1 (es)
JP (1) JP7424981B2 (es)
KR (1) KR102739356B1 (es)
CN (1) CN111065748B (es)
AU (1) AU2018332318B2 (es)
BR (1) BR112020004439A2 (es)
CA (1) CA3071219A1 (es)
EA (1) EA202090715A1 (es)
IL (1) IL272465A (es)
MX (1) MX2020002532A (es)
PH (1) PH12020500354A1 (es)
SG (1) SG11202001111QA (es)
WO (1) WO2019053233A1 (es)
ZA (1) ZA202001528B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170254A1 (en) 2017-03-15 2018-09-20 Georgetown University Treating cancer with a cck receptor inhibitor and an immune checkpoint inhibitor
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
IT201900005700A1 (it) * 2019-04-12 2020-10-12 Metadeq Ltd Nuovo marcatore di patologia e suoi usi
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
JP7741800B2 (ja) * 2019-10-28 2025-09-18 ジェンフィット 抗酸化性質を有する併用療法
CN111549123B (zh) * 2020-06-12 2022-10-21 中山大学附属第三医院 环状rna 0089762的检测试剂盒及其应用
CA3187071A1 (en) * 2020-08-03 2022-02-10 Zouher Majd Method for nash risk assessment
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof
CN112712896B (zh) * 2021-03-26 2023-03-07 深圳市绘云生物科技有限公司 用于受试体检测非酒精性脂肪性肝病状态的诊断装置及计算机系统
WO2023191555A1 (ko) 2022-03-30 2023-10-05 국립암센터 만성 간질환 위험도 예측, 진단 또는 예후 예측용 마커로서 ifi16 돌연변이 유전자 및 이의 용도
WO2024010753A1 (en) * 2022-07-06 2024-01-11 Georgetown University Mirna biomarkers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
EP3285072B1 (en) * 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
FR2953220B1 (fr) 2009-12-01 2012-11-23 Oreal Signature microarn de la differenciation epidermique et utilisations
US9221751B2 (en) * 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2013166363A2 (en) * 2012-05-03 2013-11-07 The Johns Hopkins University Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
ES2891347T3 (es) * 2015-09-14 2022-01-27 Genfit Métodos para diagnosticar y evaluar la esteatohepatitis no alcohólica

Also Published As

Publication number Publication date
JP7424981B2 (ja) 2024-01-30
PH12020500354A1 (en) 2021-01-25
EP3684954B1 (en) 2025-11-26
CN111065748B (zh) 2024-04-09
BR112020004439A2 (pt) 2020-10-06
CA3071219A1 (en) 2019-03-21
WO2019053233A1 (en) 2019-03-21
EA202090715A1 (ru) 2020-07-15
SG11202001111QA (en) 2020-03-30
EP3684954C0 (en) 2025-11-26
IL272465A (en) 2020-03-31
KR20200051676A (ko) 2020-05-13
US11519034B2 (en) 2022-12-06
KR102739356B1 (ko) 2024-12-05
EP3684954A1 (en) 2020-07-29
CN111065748A (zh) 2020-04-24
JP2021502109A (ja) 2021-01-28
AU2018332318A1 (en) 2020-02-20
ZA202001528B (en) 2024-09-25
US20200216901A1 (en) 2020-07-09
AU2018332318B2 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
MX2020002532A (es) Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PT3635009T (pt) Composições e métodos para internalização de enzimas
CL2018002359A1 (es) Métodos para usar agonistas de fxr
SV2018005661A (es) Composiciones oligonucleotidicas y sus metodos
NZ729678A (en) Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
PE20190207A1 (es) Composiciones que comprenden cepas bacterianas
CL2018000729A1 (es) Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
HK1252512A1 (zh) 向眼部遞送藥劑的方法
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX370807B (es) Anticuerpos que se unen a axl.
MX2017003121A (es) Formulaciones de anticuerpos.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
AR100374A1 (es) Composición de limpieza antimicrobiana
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
MX421186B (es) Constructos de anticuerpos.
PT3350341T (pt) Métodos para diagnosticar e avaliar esteatohepatite não alcoólica
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX379367B (es) Kit para marcaje radiactivo con galio 68 (68ga) que comprende un inhibidor de metal.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla